Maxim Group analyst Jason McCarthy upgrades Vistagen Therapeutics (NASDAQ:VTGN) from Hold to Buy and announces $30 price target.
- Headlines
- Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target
Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Price
Unlock the Full List
Latest
16:29
South Korea's Minister of Foreign Affairs: South Korea and Japan have agreed to continue improving bilateral relations.
16:26
Goldman Sachs: Assigning a "Neutral" rating to COSCO Shipping Holdings, with the Target Price raised to HKD 11.9.
COSCO Shipping Holdings+0.35%
16:24
Ma Huateng: Tencent's overseas game Business share has nearly reached half of its domestic game Business.
TENCENT-0.97%